Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for LENZ Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($2.65) per share for the year, down from their previous forecast of ($2.40). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ FY2026 earnings at ($2.70) EPS and FY2028 earnings at $1.35 EPS.

Separately, HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Trading Up 0.2 %

Shares of LENZ opened at $25.53 on Friday. The company’s fifty day moving average price is $29.69 and its 200 day moving average price is $26.72. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same period last year, the company posted ($1.33) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LENZ. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of LENZ Therapeutics in the fourth quarter worth approximately $29,000. SG Americas Securities LLC grew its holdings in shares of LENZ Therapeutics by 20.7% during the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after purchasing an additional 935 shares during the last quarter. Rhumbline Advisers raised its position in LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock worth $541,000 after purchasing an additional 1,100 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in LENZ Therapeutics in the fourth quarter worth $168,000. Finally, MetLife Investment Management LLC purchased a new stake in LENZ Therapeutics during the third quarter valued at about $182,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.